AstraZeneca (AZ) announced Thursday that its supplemental Biologic License Application has been granted priority review by the U.S. Food and Drug Administration (FDA) for the treatment of limited-stage small cell lung cancer (LS-SCLC). The regulatory decision is based on results of the ADRIATIC Phase III clinical trial in patients with…

Scientists have discovered the molecular events driving the conversion of EGFR-driven lung adenocarcinoma to an aggressive neuroendocrine cancer indistinguishable from small cell lung cancer (SCLC). For the first time, the team revealed that the Myc oncogene alone is capable of this type of histological transformation in SCLC. The discovery raises…

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center have published new research in the journal JAMA Oncology demonstrating that chemotherapy plus high doses of radiation are a safe and effective treatment for people with locally advanced non-small cell lung cancer (NSCLC) that is not suitable for surgery. The Jonsson…

Originally Aired: May 18, 2023Time: 8:00 am PT, 11:00 am ET, 17:00 CET VIEW NOW SHORTLY To be implemented in the clinic, tests must be validated and approved through a regulatory process. Coverage and procedures for mutation types vary among the many available tests. There are various methods for EGFR mutation detection,…

Cancer genetic testing company NeoGenomics and Eli Lilly and Company, through its Loxo Oncology unit, have entered into a sponsored partnership program that will see Lilly provide molecular testing for eligible patients with metastatic non-small cell lung cancer (NSCLC). The Lilly Lung Cancer Sponsored Testing Program will employ the NeoTYPE…

About 15 percent of lung cancers are classified as small cell lung cancer. Recent studies have indicated that four major subtypes of small cell lung cancer exist, yet approaches to tailor treatment of these subtypes have not yet become standard of care. Now, scientists outline new findings “MYC Drives Temporal…

Reporting in Science Advances, scientists at the Fred Hutchinson Cancer Center in Seattle have presented a blood-based test, known as liquid biopsy, capable of accurately distinguishing between types and subtypes of small cell lung cancer (SCLC), offering hope for precise diagnosis and personalized treatment plans for patients. SCLC, an aggressive…

Broadcast Date: September 19, 2024Time: 8:00 am PT, 11:00 am ET, 17:00 CET REGISTER Early diagnosis and swift treatment are critical to changing the lung cancer landscape. Aligned with this goal, blood-based testing is a valuable tool to support clinical decision-making from diagnosis through monitoring. In this webinar, Dr. Gary Pestano will…

A lung cancer patient at University College London Hospitals (UCLH) was the first to receive a novel mRNA-based vaccine designed to prime the immune system to fight cancer cells very specifically. The BioNTech immunotherapy (BNT116) is being studied in a worldwide lung cancer trial. The NIHR UCLH Clinical Research Facility…

New research from the Brigham and Women’s Hospital investigators has provided new details on different levels of cardiac risks for patient who receive radiation therapy to treat non-small cell lung cancer (NSCLC). The study, published in JACC: CardioOncology, leveraged artificial intelligence (AI) to uncover how different radiation doses impact specific…

Lung adenocarcinoma is the most common form of lung cancer in the world, and genetic markers are needed to help predict the prognosis of this disease and improve treatment outcomes. Using gene databases and patient data, a team from the Tongji Medical School and the Huazhong University of Science and…

Earlier this year, Princess Kate Middleton announced that she had cancer. The world responded with shock, partly because she’s only 42. Her 75-year-old father-in-law, King Charles, was also diagnosed almost simultaneously. His announcement drew widespread sympathy as well, but nothing like the shock that greeted Kate’s news. “She is so…

There may be new hope in the hunt for reliable ways to detect cancer early on, an area where traditional diagnostic methods often prove inadequate. By analyzing cell-free DNA (cfDNA) end-motifs, AI can now distinguish between cancer patients and healthy individuals, according to a research article published in npj Precision…

New types of lung cells that can be infected by SARS-CoV-2 have been identified by scientists at the Sanford Burnham Prebys, the University of California San Diego, and their international collaborators. These cells include some without known viral receptors. Their work could not only lead to new discoveries about COVID-19…

Researchers from the National Institutes of Health (NIH) have tested a new cellular immunotherapy whereby they engineered normal white blood cells (lymphocytes) from each patient to produce receptors that recognize and attack their specific cancer cells. Reported in Nature Medicine, the interim data in the phase II trial of people…